The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells.

EGFR MSCs breast cancer cells miR-23c miRNAs

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
06 Apr 2022
Historique:
received: 08 03 2022
revised: 31 03 2022
accepted: 01 04 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 13 4 2022
Statut: epublish

Résumé

We previously demonstrated that the epidermal growth factor receptor (EGFR) modulates in mesenchymal stem cells (MSCs) the expression of a number of genes coding for secreted proteins that promote breast cancer progression. However, the role of the EGFR in modulating in MSCs the expression of miRNAs potentially involved in the progression of breast cancer remains largely unexplored. Following small RNA-sequencing, we identified 36 miRNAs differentially expressed between MSCs untreated or treated with the EGFR ligand transforming growth factor α (TGFα), with a fold change (FC) < 0.56 or FC ≥ 1.90 (CI, 95%). KEGG analysis revealed a significant enrichment in signaling pathways involved in cancer development and progression. EGFR activation in MSCs downregulated the expression of different miRNAs, including miR-23c. EGFR signaling also reduced the secretion of miR-23c in conditioned medium from MSCs. Functional assays demonstrated that miR-23c acts as tumor suppressor in basal/claudin-low MDA-MB-231 and MDA-MB-468 cells, through the repression of IL-6R. MiR-23c downregulation promoted cell proliferation, migration and invasion of these breast cancer cell lines. Collectively, our data suggested that the EGFR signaling regulates in MSCs the expression of miRNAs that might be involved in breast cancer progression, providing novel information on the mechanisms that regulate the MSC-tumor cell cross-talk.

Identifiants

pubmed: 35406622
pii: cancers14071851
doi: 10.3390/cancers14071851
pmc: PMC8997927
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nat Rev Cancer. 2005 May;5(5):341-54
pubmed: 15864276
J Biomed Inform. 2011 Oct;44(5):839-47
pubmed: 21605702
Sci Rep. 2015 Jan 06;5:7641
pubmed: 25560734
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Cancers (Basel). 2022 Jan 15;14(2):
pubmed: 35053592
Front Oncol. 2019 Oct 22;9:1076
pubmed: 31696054
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Brief Bioinform. 2015 Nov;16(6):950-63
pubmed: 25888698
Cancer Res. 2013 Jun 1;73(11):3470-80
pubmed: 23633491
J Cell Physiol. 1998 Dec;177(3):426-38
pubmed: 9808151
Nature. 2007 Oct 11;449(7163):682-8
pubmed: 17898713
Genes Genomics. 2022 Jan 13;:
pubmed: 35023068
Br J Cancer. 2011 Sep 27;105(7):1030-8
pubmed: 21863025
Sci Signal. 2015 Mar 17;8(368):ra29
pubmed: 25783158
Sci Rep. 2019 Oct 17;9(1):14913
pubmed: 31624308
J Cell Biochem. 2012 Nov;113(11):3363-70
pubmed: 22644871
PLoS One. 2013 Jul 10;8(7):e68753
pubmed: 23874748
Oncogene. 2009 Aug 20;28(33):2940-7
pubmed: 19581928
J Cell Physiol. 2008 Mar;214(3):559-67
pubmed: 17894407
Int J Cancer. 1999 Feb 9;80(4):589-94
pubmed: 9935161
Cancer Res. 2021 Apr 15;81(8):1942-1953
pubmed: 33558335
PLoS One. 2013 Dec 31;8(12):e84256
pubmed: 24391924
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Oncotarget. 2014 Nov 15;5(21):10518-28
pubmed: 25344915
J Cell Physiol. 2011 Aug;226(8):2131-8
pubmed: 21520065
Oncogene. 2018 Apr;37(16):2137-2149
pubmed: 29367765
Br J Cancer. 2022 Mar 22;:
pubmed: 35318434
Oncotarget. 2018 Jun 29;9(50):29286-29303
pubmed: 30034618
Cancer Res. 2001 Jan 1;61(1):383-91
pubmed: 11196191
J Cell Physiol. 2006 May;207(2):420-7
pubmed: 16419029
Nature. 2008 Jan 10;451(7175):147-52
pubmed: 18185580
Clin Breast Cancer. 2022 Apr;22(3):e319-e331
pubmed: 34756687
Oncogene. 2021 Feb;40(5):1012-1026
pubmed: 33323968
Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):17-39
pubmed: 29275360
Cell Death Dis. 2017 Jul 13;8(7):e2928
pubmed: 28703807
Stem Cells Dev. 2012 Sep 1;21(13):2541-51
pubmed: 22316125
FASEB J. 2007 Nov;21(13):3763-70
pubmed: 17586727
Biomed Pharmacother. 2018 Nov;107:424-432
pubmed: 30103114
Int J Mol Sci. 2021 Oct 26;22(21):
pubmed: 34768979
J Exp Clin Cancer Res. 2019 May 14;38(1):195
pubmed: 31088482

Auteurs

Marianna Gallo (M)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.

Marianeve Carotenuto (M)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.

Daniela Frezzetti (D)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.

Rosa Camerlingo (R)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.

Cristin Roma (C)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.

Francesca Bergantino (F)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.

Nicola Normanno (N)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.

Antonella De Luca (A)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.

Classifications MeSH